[HTML][HTML] Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E …
M Terasaki, M Nagashima, K Nohtomi, K Kohashi… - PloS one, 2013 - journals.plos.org
Aim Several recent reports have revealed that dipeptidyl peptidase (DPP)-4 inhibitors have
suppressive effects on atherosclerosis in apolipoprotein E-null (Apoe−/−) mice. It remains to …
suppressive effects on atherosclerosis in apolipoprotein E-null (Apoe−/−) mice. It remains to …
Vildagliptin, a DPP-4 inhibitor, attenuates endothelial dysfunction and atherogenesis in nondiabetic apolipoprotein E-deficient mice
K Aini, D Fukuda, K Tanaka, Y Higashikuni… - International heart …, 2019 - jstage.jst.go.jp
Summary Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel antidiabetic agents with
possible vascular protection effects. Endothelial dysfunction is an initiation step in …
possible vascular protection effects. Endothelial dysfunction is an initiation step in …
[HTML][HTML] The dose-dependent organ-specific effects of a dipeptidyl peptidase-4 inhibitor on cardiovascular complications in a model of type 2 diabetes
JY Moon, JS Woo, JW Seo, A Lee, DJ Kim, YG Kim… - PLoS …, 2016 - journals.plos.org
Objective Although dipeptidyl peptidase-4 (DPP-4) inhibitors have been suggested to have
a non-glucoregulatory protective effect in various tissues, the effects of long-term inhibition of …
a non-glucoregulatory protective effect in various tissues, the effects of long-term inhibition of …
[HTML][HTML] Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
Background Diabetic patients present with an accelerated atherosclerotic process and an
increased risk for future cardiovascular events. In addition to the risk imposed by the disease …
increased risk for future cardiovascular events. In addition to the risk imposed by the disease …
A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E–deficient mice
J Matsubara, S Sugiyama, K Sugamura… - Journal of the American …, 2012 - jacc.org
Objectives: The aim of this study was to investigate the antiatherogenic effects of the
dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin (DFS). Background: The new class of …
dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin (DFS). Background: The new class of …
Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice
HM Salim, D Fukuda, Y Higashikuni, K Tanaka… - Vascular …, 2016 - Elsevier
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors have vasoprotective effects.
This study investigated whether a recently approved DPP-4 inhibitor, linagliptin (Lina) …
This study investigated whether a recently approved DPP-4 inhibitor, linagliptin (Lina) …
[HTML][HTML] Vasculoprotective effects of vildagliptin. Focus on atherogenesis
M Wiciński, K Górski, E Wódkiewicz, M Walczak… - International journal of …, 2020 - mdpi.com
Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors,
antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type …
antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type …
Suppression of abdominal aortic aneurysm formation in mice by teneligliptin, a dipeptidyl peptidase-4 inhibitor
Y Takahara, T Tokunou, T Ichiki - Journal of atherosclerosis and …, 2018 - jstage.jst.go.jp
Aim: Dipeptidyl peptidase-4 (DPP-4) inhibitors lower blood glucose levels through inhibition
of incretin degradation, which stimulates insulin secretion. Recent studies reported that DPP …
of incretin degradation, which stimulates insulin secretion. Recent studies reported that DPP …
Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic …
HM Salim, D Fukuda, Y Higashikuni, K Tanaka… - Vascular …, 2017 - Elsevier
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors have various cellular effects
that are associated with vascular protection. Here, we examined whether teneligliptin alters …
that are associated with vascular protection. Here, we examined whether teneligliptin alters …
[HTML][HTML] The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero …
N Kitao, H Miyoshi, T Furumoto, K Ono… - Cardiovascular …, 2017 - Springer
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects
in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects …
in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects …